188 related articles for article (PubMed ID: 23503426)
1. Neuroendocrine differentiation of prostate cancer.
Li Z; Chen CJ; Wang JK; Hsia E; Li W; Squires J; Sun Y; Huang J
Asian J Androl; 2013 May; 15(3):328-32. PubMed ID: 23503426
[No Abstract] [Full Text] [Related]
2. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
Chen H; Sun Y; Wu C; Magyar CE; Li X; Cheng L; Yao JL; Shen S; Osunkoya AO; Liang C; Huang J
Endocr Relat Cancer; 2012 Jun; 19(3):321-31. PubMed ID: 22389383
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Liu Q; Russell MR; Shahriari K; Jernigan DL; Lioni MI; Garcia FU; Fatatis A
Cancer Res; 2013 Jun; 73(11):3297-305. PubMed ID: 23536554
[TBL] [Abstract][Full Text] [Related]
5. [Neuroendocrine differentiation in prostate cancer].
Wu CY; Na YQ; Yao JL; di Sant'Agnese PA; Huang JT
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):565-7. PubMed ID: 17134555
[No Abstract] [Full Text] [Related]
6. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
Cheng S; Prieto-Dominguez N; Yang S; Connelly ZM; StPierre S; Rushing B; Watkins A; Shi L; Lakey M; Baiamonte LB; Fazili T; Lurie A; Corey E; Shi R; Yeh Y; Yu X
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):661-669. PubMed ID: 32313141
[TBL] [Abstract][Full Text] [Related]
7. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J
Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615
[TBL] [Abstract][Full Text] [Related]
8. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.
Lapuk AV; Wu C; Wyatt AW; McPherson A; McConeghy BJ; Brahmbhatt S; Mo F; Zoubeidi A; Anderson S; Bell RH; Haegert A; Shukin R; Wang Y; Fazli L; Hurtado-Coll A; Jones EC; Hach F; Hormozdiari F; Hajirasouliha I; Boutros PC; Bristow RG; Zhao Y; Marra MA; Fanjul A; Maher CA; Chinnaiyan AM; Rubin MA; Beltran H; Sahinalp SC; Gleave ME; Volik SV; Collins CC
J Pathol; 2012 Jul; 227(3):286-97. PubMed ID: 22553170
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.
Huang J; Yao JL; Zhang L; Bourne PA; Quinn AM; di Sant'Agnese PA; Reeder JE
Am J Pathol; 2005 Jun; 166(6):1807-15. PubMed ID: 15920165
[TBL] [Abstract][Full Text] [Related]
10. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
[TBL] [Abstract][Full Text] [Related]
11. Models of neuroendocrine prostate cancer.
Berman-Booty LD; Knudsen KE
Endocr Relat Cancer; 2015 Feb; 22(1):R33-49. PubMed ID: 25349195
[TBL] [Abstract][Full Text] [Related]
12. A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer.
Ippolito JE; Piwnica-Worms D
PLoS One; 2014; 9(2):e88667. PubMed ID: 24551133
[TBL] [Abstract][Full Text] [Related]
13. Do neuroendocrine cells come up large in small cell lung cancer?
Goldstein AS; Huang J
Cell Cycle; 2011 Nov; 10(21):3627. PubMed ID: 22024918
[No Abstract] [Full Text] [Related]
14. Neuroendocrine cells: potential cells of origin for small cell lung carcinoma.
Cheng CY; Nikitin AY
Cell Cycle; 2011 Nov; 10(21):3629-30. PubMed ID: 22024916
[No Abstract] [Full Text] [Related]
15. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Xiao GQ; Ho G; Suen C; Hurth KM
Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
[TBL] [Abstract][Full Text] [Related]
17. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
18. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
19. Correlation of PSMA-Targeted
Tosoian JJ; Gorin MA; Rowe SP; Andreas D; Szabo Z; Pienta KJ; Pomper MG; Lotan TL; Ross AE
Clin Genitourin Cancer; 2017 Feb; 15(1):e65-e68. PubMed ID: 27751686
[No Abstract] [Full Text] [Related]
20. Small cell lung cancer: new insights into origins.
MacPherson D
Cell Cycle; 2011 Oct; 10(20):3432. PubMed ID: 22030465
[No Abstract] [Full Text] [Related]
[Next] [New Search]
